This compound has been confirmed to be a highly effective reversible inhibitor of LSD1, showing effective targeted induction of cell differentiation in acute myeloid leukemia (AML) and small-cell lung cancer (SCLC) cell lines, and demonstrating anti-tumor efficacy in patient-derived xenograft (PDX) SCLC models. Here, KDM1A is linked to acute myeloid leukemia.